Skip to main content
Addgene

pLX304-BCL-XL-499R
(Plasmid #203574)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 203574 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLX304
  • Backbone size w/o insert (bp) 9377
  • Total vector size (bp) 8428
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Blasticidin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    30°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    BCL2L1
  • Alt name
    BCL2 like 1
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    774
  • Mutation
    silent point mutations introduced to make it resistant to shRNA (TRCN0000033499)
  • GenBank ID
    598
  • Entrez Gene
    BCL2L1 (a.k.a. BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52)
  • Promoter CMV
  • Tag / Fusion Protein
    • V5- tagged (C terminal on backbone)

Cloning Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

BCL-XL was sub-cloned, using gateway cloning, from a BCL-XL-GFP fusion construct obtained from Dr. Ruth Keri's laboratory (CCF). Silent mutations were introduced in the shRNA-recognition sequence using Site-directed mutagenesis.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLX304-BCL-XL-499R was a gift from Abhishek Chakraborty (Addgene plasmid # 203574 ; http://n2t.net/addgene:203574 ; RRID:Addgene_203574)

  • For your References section:

    A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Grubb T, Maganti S, Krill-Burger JM, Fraser C, Stransky L, Radivoyevitch T, Sarosiek KA, Vazquez F, Kaelin WG, Chakraborty AA. Clin Cancer Res. 2022 Nov 1;28(21):4689-4701. doi: 10.1158/1078-0432.CCR-22-0669. 10.1158/1078-0432.CCR-22-0669 PubMed 35776130
Related items: